AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Oct 2017 07:00 AM
RNS
FDA accepts sBLA file for Imfinzi; priority review
09 Oct 2017 07:00 AM
RNS
FDA grants Tagrisso BTD for 1st-line EGFR nsclc
02 Oct 2017 03:00 PM
RNS
Total Voting Rights
26 Sep 2017 12:00 PM
RNS
Director/PDMR Shareholding
14 Sep 2017 07:00 AM
RNS
Aspen acquires remaining rights to AZ anaesthetics
11 Sep 2017 07:00 AM
RNS
IMFINZI superior PFS in Stage III lung cancer
11 Sep 2017 07:00 AM
RNS
Tagrisso potential standard of care in lung cancer
07 Sep 2017 12:39 PM
RNS
Celgene and AZ update on Fusion trial programme
07 Sep 2017 07:00 AM
RNS
AZ tezepelumab cuts exacerbations in severe asthma
07 Sep 2017 07:00 AM
RNS
AZ Duaklir improves lung function in COPD patients
05 Sep 2017 07:00 AM
RNS
Directorate Change
01 Sep 2017 03:00 PM
RNS
Total Voting Rights
29 Aug 2017 07:00 AM
RNS
Faslodex gets US FDA OK for expanded use in breast
18 Aug 2017 07:00 AM
RNS
Lynparza gets broad FDA approval in ovarian cancer
16 Aug 2017 07:00 AM
RNS
Directorate Change
14 Aug 2017 04:30 PM
RNS
Holding(s) in Company
10 Aug 2017 01:30 PM
RNS
Publication of a Prospectus
02 Aug 2017 07:00 AM
RNS
AZ acalabrutinib submission accepted by US FDA
01 Aug 2017 03:00 PM
RNS
Total Voting Rights
01 Aug 2017 07:00 AM
RNS
BTD for AZ's acalabrutinib in mantle cell lymphoma
31 Jul 2017 07:00 AM
RNS
Imfinzi granted BTD by US FDA for Stage III nsclc
28 Jul 2017 11:00 AM
RNS
Director/PDMR Shareholding
27 Jul 2017 07:15 AM
RNS
Tagrisso significantly improves FLAURA
27 Jul 2017 07:11 AM
RNS
AZ reports initial results from MYSTIC lung trial
27 Jul 2017 07:06 AM
RNS
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27 Jul 2017 07:00 AM
RNS
AstraZeneca PLC - H1 2017 Results
26 Jul 2017 04:46 PM
RNS
Faslodex receives EU approval for 1L breast cancer
21 Jul 2017 03:45 PM
RNS
Holding(s) in Company
03 Jul 2017 02:59 PM
RNS
Total Voting Rights
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23 Jun 2017 12:46 PM
RNS
Faslodex CHMP positive opinion in 1L breast cancer
07 Jun 2017 07:13 AM
RNS
AZ agreement with Grünenthal for rights to Zomig
06 Jun 2017 07:00 AM
RNS
ASTRAZENECA PRICES A $2BN BOND ISSUE
05 Jun 2017 07:00 AM
RNS
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
01 Jun 2017 03:00 PM
RNS
Block listing Interim Review
01 Jun 2017 03:00 PM
RNS
Total Voting Rights
31 May 2017 07:00 AM
RNS
Directorate Change
24 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
23 May 2017 07:00 AM
RNS
Bydureon EXSCEL trial meets T2D safety objective
22 May 2017 07:00 AM
RNS
AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
12 May 2017 07:00 AM
RNS
IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10 May 2017 07:00 AM
RNS
AZ updates on tralokinumab trial in severe asthma
02 May 2017 02:00 PM
RNS
Total Voting Rights
02 May 2017 07:00 AM
RNS
DURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27 Apr 2017 05:30 PM
RNS
Result of AGM
27 Apr 2017 07:00 AM
RNS
AstraZeneca: Q1 2017 Results
25 Apr 2017 01:30 PM
RNS
TAGRISSO RECEIVES FULL APPROVAL IN THE EU
03 Apr 2017 03:00 PM
RNS
Total Voting Rights
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100